MediciNova, Inc. Stock

$1.23

3.91% today

Nasdaq, Jul 15, 05:07 pm CET

ISIN

US58468P2065

Symbol

MNOV

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

MediciNova, Inc. Stock price

$1.28

-4.05 75.99% 5Y

Nasdaq, Closing price Mon, Jul 14 2025

+0.01 0.80%

ISIN

US58468P2065

Symbol

MNOV

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$62.8m

Enterprise Value

$26.2m

Net debt

positive

Cash

$36.6m

Shares outstanding

49.1m

Valuation (TTM | estimate)

P/E

- | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

1.3

Financial Health

Equity Ratio

94.0%

Return on Equity

-21.1%

ROCE

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

- | $0.0

EBITDA

- | -

EBIT

- | $-30.2m

Net Income

- | $-20.0m

Free Cash Flow

$-10.6m

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Get Started for Free Today

MediciNova, Inc. Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a MediciNova, Inc. forecast:

7x Buy

88%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a MediciNova, Inc. forecast:

Buy

88%

Hold

13%

Analyst Estimates with Stock Price Targets

Financial data from MediciNova, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	4.13 4.13	21% 21% -
- Research and Development Expense	5.41 5.41	4% 4% -
EBITDA	-9.52 -9.52	4% 4% -
- Depreciation and Amortization	0.02 0.02	0% 0% -
EBIT (Operating Income) EBIT	-9.54 -9.54	4% 4% -
Net Profit	-8.30 -8.30	3% 3% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

MediciNova, Inc. Stock News

Neutral

GlobeNewsWire

●

3 months ago

MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025

LA JOLLA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces that their CEO, Yuichi Iwaki, MD, Ph.D., and CBO, David H. Crean, Ph.D., will be participating in investor meetings at D. Boral Capital's, Inaugural DBC Confer...

Neutral

GlobeNewsWire

●

3 months ago

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

LA JOLLA, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced enrollment of the first patient in the NIH-funded Expanded Access Program (EAP) trial to evaluate MN-166 (ibudilast) in patients with Amyotrophic Lateral Sclero...

Company Profile

MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of serious diseases for the treatment of diseases with unmet medical need. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.

Head office	United States
CEO	Yuichi Iwaki
Employees	13
Founded	2000
Website	medicinova.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now